News & Updates

Patients with type 2 diabetes (T2D) who received combined treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a much lower risk of major adverse cardiovascular events (MACE) and serious renal events than those treated with either drug class alone, suggests a recent study.

Men with prostate cancer who consume higher amounts of plant-based foods have a lower risk of cancer progression, as shown in a longitudinal observational cohort study.

The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.

A higher ratio of blood urea nitrogen to serum albumin is indicative of worse outcomes and disease severity in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a study.

Taking aspirin in the adjuvant setting does not appear to lower the risk of recurrence or improve survival in patients with high-risk nonmetastatic breast cancer, as shown in the results of the phase III Alliance A011502 trial.

Sexual disorders are common among breast cancer patients, and such problems may continue for up to 2 years after the cancer diagnosis, according to a study. Notably, a communication gap regarding sexuality persists between patients and healthcare providers.